Comparing Irreversible Electroporation and Radiofrequency Ablation for Liver Cancer Treatment
Author Information
Author(s): Cheng Chao, Xu Min, Pan Jinhua, Chen Qiang, Li Kai, Xu Dong, Jing Xiang, Lu Qiang, Yang Hong, Zhao Qiyu, Deng Zhuang, Jiang Tian’an
Primary Institution: The First Affiliated Hospital, Zhejiang University School of Medicine
Hypothesis
This study aims to conduct a randomized controlled clinical trial comparing the efficacy of irreversible electroporation (IRE) with radiofrequency ablation (RFA) in the treatment of liver cancer.
Conclusion
The preliminary results suggest that both RFA and IRE are effective in the treatment of hepatocellular carcinoma (HCC), providing strong evidence for the use of IRE.
Supporting Evidence
- Both IRE and RFA achieved a 100% complete ablation rate at 1 month.
- Lesions in the IRE group showed significant shrinkage after 1 month.
- One major adverse event occurred in the RFA group.
Takeaway
This study is looking at two ways to treat liver cancer to see which one works better. Both methods seem to help, but more research is needed.
Methodology
A multicenter, randomized, parallel-controlled non-inferiority clinical trial comparing IRE and RFA for hepatocellular carcinoma.
Potential Biases
Selection bias may occur due to the non-blinding of treatment allocation.
Limitations
The study cannot blind patients or surgeons during the clinical procedure, which may introduce bias.
Participant Demographics
Patients aged 18 to 80 years with hepatocellular carcinoma, median age 59.1 years.
Statistical Information
P-Value
p<0.0001 for ALT and AST increases post-procedure.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website